Sodium benzoate for the treatment of behavioral and psychological symptoms of dementia (BPSD): A randomized, double-blind, placebo-controlled, 6-week trial.

Chia-Hung Lin; PK Chen; SH Wang; HY Lane

doi:10.1177/0269881119849815

Sodium benzoate for the treatment of behavioral and psychological symptoms of dementia (BPSD): A randomized, double-blind, placebo-controlled, 6-week trial.

Chia-Hung Lin, PK Chen, SH Wang, HY Lane

School of Traditional Chinese Medicine

Research output: Contribution to journal › Journal Article › peer-review

22 Scopus citations

Abstract

Sodium benzoate, a D-amino acid oxidase (DAAO) inhibitor, improved cognitive function of early-phase Alzheimer's disease (AD) after 24-week treatment. This study examined benzoate treatment for behavioral and psychological symptoms of dementia (BPSD). In a double-blind, 6-week trial, 97 patients with BPSD were randomized to receive placebo or benzoate (mean dose: 622.0 mg/day). The primary outcomes were ADAS-cog and BEHAVE-AD. Two treatments showed similar safety and primary and secondary outcomes. Compared to antecedent 24-week, higher-dose treatment for early-phase AD, benzoate appeared ineffective in this 6-week trial. Longer-duration, higher-dose trials are warranted to clarify its efficacy for BPSD.

Original language	American English
Pages (from-to)	269881119849815
Journal	Journal of psychopharmacology (Oxford, England)
Volume	33
Issue number	8
DOIs	https://doi.org/10.1177/0269881119849815
State	Published - 2019

Access to Document

10.1177/0269881119849815

Cite this

@article{f551f0962b26465b90e25ff7e93a8203,

title = "Sodium benzoate for the treatment of behavioral and psychological symptoms of dementia (BPSD): A randomized, double-blind, placebo-controlled, 6-week trial.",

abstract = "Sodium benzoate, a D-amino acid oxidase (DAAO) inhibitor, improved cognitive function of early-phase Alzheimer's disease (AD) after 24-week treatment. This study examined benzoate treatment for behavioral and psychological symptoms of dementia (BPSD). In a double-blind, 6-week trial, 97 patients with BPSD were randomized to receive placebo or benzoate (mean dose: 622.0 mg/day). The primary outcomes were ADAS-cog and BEHAVE-AD. Two treatments showed similar safety and primary and secondary outcomes. Compared to antecedent 24-week, higher-dose treatment for early-phase AD, benzoate appeared ineffective in this 6-week trial. Longer-duration, higher-dose trials are warranted to clarify its efficacy for BPSD.",

author = "Chia-Hung Lin and PK Chen and SH Wang and HY Lane",

year = "2019",

doi = "10.1177/0269881119849815",

language = "American English",

volume = "33",

pages = "269881119849815",

journal = "Journal of psychopharmacology (Oxford, England)",

issn = "0269-8811",

publisher = "SAGE Publications Ltd",

number = "8",

}

Sodium benzoate for the treatment of behavioral and psychological symptoms of dementia (BPSD): A randomized, double-blind, placebo-controlled, 6-week trial. / Lin, Chia-Hung; Chen, PK; Wang, SH et al.
In: Journal of psychopharmacology (Oxford, England), Vol. 33, No. 8, 2019, p. 269881119849815.

Research output: Contribution to journal › Journal Article › peer-review

TY - JOUR

T1 - Sodium benzoate for the treatment of behavioral and psychological symptoms of dementia (BPSD): A randomized, double-blind, placebo-controlled, 6-week trial.

AU - Lin, Chia-Hung

AU - Chen, PK

AU - Wang, SH

AU - Lane, HY

PY - 2019

Y1 - 2019

N2 - Sodium benzoate, a D-amino acid oxidase (DAAO) inhibitor, improved cognitive function of early-phase Alzheimer's disease (AD) after 24-week treatment. This study examined benzoate treatment for behavioral and psychological symptoms of dementia (BPSD). In a double-blind, 6-week trial, 97 patients with BPSD were randomized to receive placebo or benzoate (mean dose: 622.0 mg/day). The primary outcomes were ADAS-cog and BEHAVE-AD. Two treatments showed similar safety and primary and secondary outcomes. Compared to antecedent 24-week, higher-dose treatment for early-phase AD, benzoate appeared ineffective in this 6-week trial. Longer-duration, higher-dose trials are warranted to clarify its efficacy for BPSD.

AB - Sodium benzoate, a D-amino acid oxidase (DAAO) inhibitor, improved cognitive function of early-phase Alzheimer's disease (AD) after 24-week treatment. This study examined benzoate treatment for behavioral and psychological symptoms of dementia (BPSD). In a double-blind, 6-week trial, 97 patients with BPSD were randomized to receive placebo or benzoate (mean dose: 622.0 mg/day). The primary outcomes were ADAS-cog and BEHAVE-AD. Two treatments showed similar safety and primary and secondary outcomes. Compared to antecedent 24-week, higher-dose treatment for early-phase AD, benzoate appeared ineffective in this 6-week trial. Longer-duration, higher-dose trials are warranted to clarify its efficacy for BPSD.

U2 - 10.1177/0269881119849815

DO - 10.1177/0269881119849815

M3 - Journal Article

C2 - 31113277

SN - 0269-8811

VL - 33

SP - 269881119849815

JO - Journal of psychopharmacology (Oxford, England)

JF - Journal of psychopharmacology (Oxford, England)

IS - 8

ER -

Sodium benzoate for the treatment of behavioral and psychological symptoms of dementia (BPSD): A randomized, double-blind, placebo-controlled, 6-week trial.

Abstract

Access to Document

Fingerprint

Cite this